Drug-induced Parkinson-like events: a real-world study from 2004 to the first quarter of 2024 based on FAERS
BackgroundTimely identification of drug-induced Parkinson-like events is essential to improve clinical management and enhance patients’ quality of life. However, there is a significant lack of studies addressing these events in real-world settings.MethodsTo bridge this gap, we analyzed adverse event...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2024.1529260/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841561079047520256 |
|---|---|
| author | Ke Wang Ke Wang Junyan Chen Mingquan Huang Xinhao Zeng Xiaoqun Ren Xiuqiong Liu Chao Tao Chao Tao Liuxuan Yang Liuxuan Yang Jinlu Shang Meiling Zhou |
| author_facet | Ke Wang Ke Wang Junyan Chen Mingquan Huang Xinhao Zeng Xiaoqun Ren Xiuqiong Liu Chao Tao Chao Tao Liuxuan Yang Liuxuan Yang Jinlu Shang Meiling Zhou |
| author_sort | Ke Wang |
| collection | DOAJ |
| description | BackgroundTimely identification of drug-induced Parkinson-like events is essential to improve clinical management and enhance patients’ quality of life. However, there is a significant lack of studies addressing these events in real-world settings.MethodsTo bridge this gap, we analyzed adverse event (AE) reports related to Parkinson-like events from the FDA Adverse Event Reporting System (FAERS) database from the first quarter of 2004 to the first quarter of 2024. Our objective was to summarize a list of potential drugs at high risk for Parkinson-like events and their corresponding proportions of AE reports.ResultsAs a result, a total of 54,639 AE reports linked to Parkinson-like events involving 1,224 drugs were identified. Among these, carbidopa/levodopa exhibited the highest number of reports, followed by baclofen and pimavanserin. The most frequently reported drug class was antiparkinsonian drugs and psycholeptics, followed by psychoanaleptics. Using two disproportionate analysis methods, the reporting odds ratio and proportional reporting ratio, we found that 136 drugs exhibited positive results in both methods, while 1,063 drugs did not show any positive signals.ConclusionThis study provides a comprehensive pharmacovigilance analysis of drugs associated with Parkinson-like events, aiming to promote rational drug use and inform clinical practice. |
| format | Article |
| id | doaj-art-f3d976672a2b4e1ab0ef8c2f6706c1db |
| institution | Kabale University |
| issn | 1663-9812 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj-art-f3d976672a2b4e1ab0ef8c2f6706c1db2025-01-03T06:46:57ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122025-01-011510.3389/fphar.2024.15292601529260Drug-induced Parkinson-like events: a real-world study from 2004 to the first quarter of 2024 based on FAERSKe Wang0Ke Wang1Junyan Chen2Mingquan Huang3Xinhao Zeng4Xiaoqun Ren5Xiuqiong Liu6Chao Tao7Chao Tao8Liuxuan Yang9Liuxuan Yang10Jinlu Shang11Meiling Zhou12Department of Pharmacy, The Affiliated Hospital, Southwest Medical University, Luzhou, ChinaDepartment of Clinical Pharmacy, School of Pharmacy, Southwest Medical University, Luzhou, ChinaDepartment of Cardiothoracic Surgery, Luzhou People’s Hospital, Luzhou, ChinaSichuan Treatment Center for Gynaecologic and Breast Diseases (Breast Surgery), The Affiliated Hospital of Southwest Medical University, Luzhou, ChinaDepartment of Pediatric Surgery, The Affiliated Hospital of Southwest Medical University, Sichuan Clinical Research Center for Birth Defects, Luzhou, ChinaDepartment of Pharmacy, The Affiliated Hospital, Southwest Medical University, Luzhou, ChinaDepartment of Pharmacy, West China Hospital Sichuan University Jintang Hospital, Chengdu, ChinaDepartment of Pharmacy, The Affiliated Hospital, Southwest Medical University, Luzhou, ChinaDepartment of Clinical Pharmacy, School of Pharmacy, Southwest Medical University, Luzhou, ChinaDepartment of Pharmacy, The Affiliated Hospital, Southwest Medical University, Luzhou, ChinaDepartment of Clinical Pharmacy, School of Pharmacy, Southwest Medical University, Luzhou, ChinaDepartment of Pharmacy, West China Hospital Sichuan University Jintang Hospital, Chengdu, ChinaDepartment of Pharmacy, The Affiliated Hospital, Southwest Medical University, Luzhou, ChinaBackgroundTimely identification of drug-induced Parkinson-like events is essential to improve clinical management and enhance patients’ quality of life. However, there is a significant lack of studies addressing these events in real-world settings.MethodsTo bridge this gap, we analyzed adverse event (AE) reports related to Parkinson-like events from the FDA Adverse Event Reporting System (FAERS) database from the first quarter of 2004 to the first quarter of 2024. Our objective was to summarize a list of potential drugs at high risk for Parkinson-like events and their corresponding proportions of AE reports.ResultsAs a result, a total of 54,639 AE reports linked to Parkinson-like events involving 1,224 drugs were identified. Among these, carbidopa/levodopa exhibited the highest number of reports, followed by baclofen and pimavanserin. The most frequently reported drug class was antiparkinsonian drugs and psycholeptics, followed by psychoanaleptics. Using two disproportionate analysis methods, the reporting odds ratio and proportional reporting ratio, we found that 136 drugs exhibited positive results in both methods, while 1,063 drugs did not show any positive signals.ConclusionThis study provides a comprehensive pharmacovigilance analysis of drugs associated with Parkinson-like events, aiming to promote rational drug use and inform clinical practice.https://www.frontiersin.org/articles/10.3389/fphar.2024.1529260/fullParkinson-like eventspharmacovigilancedrug safetyantiparkinsonian agentsadverse eventFAERS |
| spellingShingle | Ke Wang Ke Wang Junyan Chen Mingquan Huang Xinhao Zeng Xiaoqun Ren Xiuqiong Liu Chao Tao Chao Tao Liuxuan Yang Liuxuan Yang Jinlu Shang Meiling Zhou Drug-induced Parkinson-like events: a real-world study from 2004 to the first quarter of 2024 based on FAERS Frontiers in Pharmacology Parkinson-like events pharmacovigilance drug safety antiparkinsonian agents adverse event FAERS |
| title | Drug-induced Parkinson-like events: a real-world study from 2004 to the first quarter of 2024 based on FAERS |
| title_full | Drug-induced Parkinson-like events: a real-world study from 2004 to the first quarter of 2024 based on FAERS |
| title_fullStr | Drug-induced Parkinson-like events: a real-world study from 2004 to the first quarter of 2024 based on FAERS |
| title_full_unstemmed | Drug-induced Parkinson-like events: a real-world study from 2004 to the first quarter of 2024 based on FAERS |
| title_short | Drug-induced Parkinson-like events: a real-world study from 2004 to the first quarter of 2024 based on FAERS |
| title_sort | drug induced parkinson like events a real world study from 2004 to the first quarter of 2024 based on faers |
| topic | Parkinson-like events pharmacovigilance drug safety antiparkinsonian agents adverse event FAERS |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2024.1529260/full |
| work_keys_str_mv | AT kewang druginducedparkinsonlikeeventsarealworldstudyfrom2004tothefirstquarterof2024basedonfaers AT kewang druginducedparkinsonlikeeventsarealworldstudyfrom2004tothefirstquarterof2024basedonfaers AT junyanchen druginducedparkinsonlikeeventsarealworldstudyfrom2004tothefirstquarterof2024basedonfaers AT mingquanhuang druginducedparkinsonlikeeventsarealworldstudyfrom2004tothefirstquarterof2024basedonfaers AT xinhaozeng druginducedparkinsonlikeeventsarealworldstudyfrom2004tothefirstquarterof2024basedonfaers AT xiaoqunren druginducedparkinsonlikeeventsarealworldstudyfrom2004tothefirstquarterof2024basedonfaers AT xiuqiongliu druginducedparkinsonlikeeventsarealworldstudyfrom2004tothefirstquarterof2024basedonfaers AT chaotao druginducedparkinsonlikeeventsarealworldstudyfrom2004tothefirstquarterof2024basedonfaers AT chaotao druginducedparkinsonlikeeventsarealworldstudyfrom2004tothefirstquarterof2024basedonfaers AT liuxuanyang druginducedparkinsonlikeeventsarealworldstudyfrom2004tothefirstquarterof2024basedonfaers AT liuxuanyang druginducedparkinsonlikeeventsarealworldstudyfrom2004tothefirstquarterof2024basedonfaers AT jinlushang druginducedparkinsonlikeeventsarealworldstudyfrom2004tothefirstquarterof2024basedonfaers AT meilingzhou druginducedparkinsonlikeeventsarealworldstudyfrom2004tothefirstquarterof2024basedonfaers |